Literature DB >> 16172134

Active repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory factor-4.

Kayo Yoshida1, Kazuo Yamamoto, Tomoko Kohno, Noriko Hironaka, Kiyoshi Yasui, Chojiro Kojima, Hiroshi Mukae, Jun-ichi Kadota, Shoichi Suzuki, Kiri Honma, Shigeru Kohno, Toshifumi Matsuyama.   

Abstract

IFN regulatory factor-4 (IRF-4) is a transcription factor that is involved in the development and the functions of lymphocytes, macrophages and dendritic cells. Despite their critical roles in immune system regulation, the target genes controlled by IRF-4 are poorly understood. In this study, we determined the consensus DNA-binding sequences preferred for IRF-4 by in vitro binding site selections. IRF-4 preferentially bound to the sequences containing tandem repeats of 5'-GAAA-3', flanked by CpC, in most cases. IRF-4 repressed the promoter bearing tandem copies of the selected binding sequence, while IRF-1 activated the same constructs. Interestingly, the IRF-1-dependent transactivation is inhibited in the presence of IRF-4, but not IRF-2. A series of deletion mutants of IRF-4 revealed that its DNA-binding domain was necessary and sufficient to antagonize the IRF-1-dependent transactivation. This dominant negative action of IRF-4 over IRF-1 was also observed in a natural promoter context, such as the TRAIL gene. These results indicate that IRF-4 acts as a natural antagonist against IRF-1 in immune cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16172134     DOI: 10.1093/intimm/dxh324

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  13 in total

Review 1.  The IRF family, revisited.

Authors:  A Paun; P M Pitha
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

2.  Critical role of IRF1 and BATF in forming chromatin landscape during type 1 regulatory cell differentiation.

Authors:  Katarzyna Karwacz; Emily R Miraldi; Maria Pokrovskii; Asaf Madi; Nir Yosef; Ivo Wortman; Xi Chen; Aaron Watters; Nicholas Carriero; Amit Awasthi; Aviv Regev; Richard Bonneau; Dan Littman; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2017-02-06       Impact factor: 25.606

3.  Negative regulation of Toll-like-receptor signaling by IRF-4.

Authors:  Hideo Negishi; Yusuke Ohba; Hideyuki Yanai; Akinori Takaoka; Kiri Honma; Katsuyuki Yui; Toshifumi Matsuyama; Tadatsugu Taniguchi; Kenya Honda
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-19       Impact factor: 11.205

4.  Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells.

Authors:  Radmila Hrdlicková; Jirí Nehyba; Henry R Bose
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

5.  Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in naive vs. effector/memory CD4+ T cells.

Authors:  Kiri Honma; Daisuke Kimura; Norio Tominaga; Mana Miyakoda; Toshifumi Matsuyama; Katsuyuki Yui
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-03       Impact factor: 11.205

6.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Authors:  Tomohiro Watanabe; Naoki Asano; Peter J Murray; Keiko Ozato; Prafullakumar Tailor; Ivan J Fuss; Atsushi Kitani; Warren Strober
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 7.  Molecular pathways regulating macrophage polarization: implications for atherosclerosis.

Authors:  Marten A Hoeksema; J Lauran Stöger; Menno P J de Winther
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

8.  Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.

Authors:  Teresa Rodríguez; Rosa Méndez; Ana Del Campo; Pilar Jiménez; Natalia Aptsiauri; Federico Garrido; Francisco Ruiz-Cabello
Journal:  BMC Cancer       Date:  2007-02-23       Impact factor: 4.430

9.  SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.

Authors:  Satoru Yokoyama; Atsushi Takahashi; Ryota Kikuchi; Soshi Nishibu; Jennifer A Lo; Miroslav Hejna; Wooyoung M Moon; Shinichiro Kato; Yue Zhou; F Stephen Hodi; Jun S Song; Hiroaki Sakurai; David E Fisher; Yoshihiro Hayakawa
Journal:  Cancer Res       Date:  2021-11-02       Impact factor: 13.312

10.  The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Authors:  Cinzia Fionda; Maria Pia Abruzzese; Alessandra Zingoni; Francesca Cecere; Elisabetta Vulpis; Giovanna Peruzzi; Alessandra Soriani; Rosa Molfetta; Rossella Paolini; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Angela Santoni; Marco Cippitelli
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.